Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Kentaro Yamazaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6269-9345; OpenAlex author ID A5038655401. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 11

  1. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  2. Clinical significance of resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis. Co-author DOI 10.1016/j.surg.2024.10.016↗
  3. Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases. Co-author DOI 10.1097/mpa.0000000000002485↗
  4. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  5. Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. Last author DOI 10.1038/s10038-022-01097-y↗
  6. Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin. Last author DOI 10.1186/s12885-023-10542-w↗
  7. Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study. Last author DOI 10.1007/s10637-022-01221-x↗
  8. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Ven… Co-author DOI 10.1245/s10434-022-11628-8↗
  9. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated … Co-author DOI 10.1245/s10434-022-11662-6↗
  10. Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.09.011↗
  11. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Co-author DOI 10.1097/mpa.0b013e3182156e1b↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teiichi Sugiura · 6 shared papers, 2017–2025 · strength 1.03
  2. Katsuhiko Uesaka · 5 shared papers, 2011–2025 · strength 0.85
  3. Akiko Todaka · 6 shared papers, 2017–2023 · strength 0.83
  4. Ryo Ashida · 4 shared papers, 2022–2025 · strength 0.83
  5. Katsuhisa Ohgi · 4 shared papers, 2022–2025 · strength 0.83
  6. Mihoko Yamada · 3 shared papers, 2022–2025 · strength 0.56
  7. Hirofumi Yasui · 4 shared papers, 2017–2023 · strength 0.53
  8. Yoshiyasu Kato · 2 shared papers, 2025 · strength 0.52
  9. Takeshi Kawakami · 3 shared papers, 2022–2023 · strength 0.47
  10. Hidemasa Kubo · 2 shared papers, 2022 · strength 0.30
  11. Jun Shibamoto · 1 shared paper, 2025 · strength 0.26
  12. Satoaki Nakamura · 1 shared paper, 2026 · strength 0.20
  13. Yusuke Sano · 1 shared paper, 2026 · strength 0.20
  14. Junki Mizusawa · 1 shared paper, 2026 · strength 0.20
  15. Tatsuya Ioka · 1 shared paper, 2026 · strength 0.20
  16. Yoshito Komatsu · 1 shared paper, 2026 · strength 0.20
  17. Satoshi Kobayashi · 1 shared paper, 2026 · strength 0.20
  18. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  19. Masafumi Ikeda · 1 shared paper, 2026 · strength 0.20
  20. Yukiko Takayama · 1 shared paper, 2026 · strength 0.20
  21. Kazuo Hara · 1 shared paper, 2026 · strength 0.20
  22. Masato Ozaka · 1 shared paper, 2026 · strength 0.20
  23. Fumio Nagashima · 1 shared paper, 2026 · strength 0.20
  24. Masashi Kanai · 1 shared paper, 2026 · strength 0.20
  25. Junji Furuse · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.